Outcome of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis and solid organ transplantation.

Matilde B Ørum,Frederikke F Rönsholt,Majbritt Jeppesen,Elisabeth Bendstrup,Terese L Katzenstein,Peter Ott,Michael Perch,Tacjana Pressler,Tavs Qvist,Søren Jensen-Fangel

Pediatric pulmonology（2022）

引用 5|浏览9

暂无评分

摘要

We report a case series of four patients with cystic fibrosis (CF) and previous solid organ transplantation (SOT) receiving elexacaftor/tezacaftor/ivacaftor therapy for 6 months or more. Data was collected retrospectively. The treatment was well tolerated and all patients reported subjective improvements.

查看译文

关键词

CFTR therapy,ETI,cystic fibrosis,cystic fibrosis transmembrane conductance regulator therapy,solid organ transplantation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要